Epidauros and InPheno to Co-Market Their PGx Services | GenomeWeb
NEW YORK (GenomeWeb News) — Epidauros and InPheno earlier this week said they plan to co-market their pharmacogenomic and phenotypic services to drug developers as a single service.
“We are trying to bring both genotype and phenotype analysis together because genetic analysis alone is not sufficient to predict statistical variance in clinical outcomes,” Hans Peter Arnold, director of business development and marketing at Epidauros, told GenomeWeb News this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.